CinCor Pharma : Corporate Presentation – May 2022

Corporate Presentation

May 2022

NASDAQ: CINC

Forward Looking Statements Disclaimer

Matters discussed in this presentation may constitute forward-looking statements.

This presentation contains certain forward-looking statements, including, but not limited to, statements related to CinCor's business in general; the results and timing of CinCor's ongoing and planned clinical trials; the anticipated timing of disclosure of results of clinical trials; the progress of CinCor's research and development programs and clinical trials and studies, including enrollment and retention in clinical trials; plans for initiating future clinical trials and studies; the therapeutic potential of baxdrostat (CIN- 107); CinCor's clinical milestones and pipeline; expectations with respect to regulatory matters; expectations with respect to human capital matters; expectations relating to and the sufficiency of CinCor's cash resources; and other statements that are not historical facts. Because such statements are subject to risks and uncertainties, actual results may differ from those expressed or implied by such forward-looking statements. Words such as "anticipates," "believes," "expected," "intends," "plan," "may", "will," "project", "estimate", "continue," "advance" and "future" or similar expressions are intended to identify forward-looking statements.

These forward-looking statements are based on CinCor's current plans, objectives, estimates, expectations and intentions, involve assumptions that may never materialize or may prove to be incorrect and inherently involve significant risks and uncertainties, including factors beyond CinCor's control, that could cause actual results, performance, or achievement to differ materially and adversely from those anticipated or implied in the statements, including, without limitation, CinCor has incurred significant operating losses since its inception; CinCor has a limited operating history and no history of commercializing products; CinCor will require substantial additional funding to finance its operations; CinCor's business is entirely dependent at this time on the success of one drug, baxdrostat (CIN-107); interim, "top-line" and preliminary data from clinical trials announced or published from time to time may change; CinCor may not be successful in its efforts to expand its pipeline beyond baxdrostat (CIN-107); success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials; enrollment and retention of patients in clinical trials could be delayed; CinCor relies and will rely on third parties to conduct, supervise and monitor existing clinical trials and potential future clinical trials; developments from the company's competitors and the marketplace for the company's products; and CinCor's business, operations and clinical development timelines and plans may be adversely affected by the evolving and ongoing COVID-19 pandemic and geopolitical events, including the ongoing military conflict between Russia and Ukraine and related sanctions against Russia, and matters related thereto; and other risks and uncertainties affecting the company, including those described under the caption "Risk Factors" and elsewhere in CinCor's annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 22, 2022, and other filings and reports that CinCor may file from time to time with the SEC, including its quarterly report on Form 10-Q for the three months ended March 31, 2022 filed with the SEC on May 10, 2022.

Other risks and uncertainties of which CinCor is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All forward-looking statements contained in this presentation speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

2

Highlights

Pipeline-in-a-Product Strategy

Focused &

Differentiated

Pipeline

Robust

Market

Opportunity

Multiple

Near-Term

Catalysts

Experienced Management

• Baxdrostat (CIN-107) is a highly selective, oral, small molecule aldosterone synthase inhibitor
• Blinded, preliminary safety from ongoing Phase 2 clinical trial shows systolic blood pressure (SBP) reduction in the 124 patients included in the review (included 2 active doses and placebo) 1
• Attractive safety profile observed to date
• Targeting multiple patient populations with significant unmet medical needs
• Hypertension indication that affects millions of patients in the US
• Phase 2 clinical trial to evaluate the safety and efficacy of baxdrostat (CIN-107) in chronic kidney disease (CKD) patients with uncontrolled blood pressure (BP)

Four ongoing Phase 2 clinical trials:

• Treatment Resistant Hypertension (rHTN) - Enrollment completed March 2022. Topline data expected in 2H 2022
• Uncontrolled Hypertension (uHTN) - Topline data expected in 2H 2022
• Chronic Kidney Disease (CKD) - Phase 2 trial initiated in April 2022
• Primary Aldosteronism (PA) - Topline data expected in 2023
• Experienced leadership and executive team with track record of success
• Scientific Advisory Board with respected experts
• Supported by top-tier healthcare investors

1 Following 12 weeks, systolic blood pressure levels declined for the 124 patients included in the review, including patients in the placebo cohort. The purpose of this blinded data review was to enable an assessment of the overall management and conduct of the trial, without unblinding any individual patient data. Due to the preliminary and blinded nature of the data, this interim data set was not subject to the standard quality control

measures typically associated with final clinical trial results.

3

CinCor Leadership

Experienced team with cardio-renal development history

Marc de Garidel	Terry Coelho, MBA	Mason Freeman, MD	Catherine Pearce, MBA, DHSc	Justin Thompson, MS
CEO	EVP, CFO, & CBDO	Chief Medical Officer	COO & Co-founder	Vice President BD
CEO of Corvidia	EVP & CFO, BioDelivery	Venture Partner 5AM	COO & Co-founder CinRx	CBO CinRx Pharma
Therapeutics, drove sale to	Systems International	Ventures	Pharma
Novo Nordisk ($2.1B)				Principal investor at
Grew Ipsen from $1.5B mkt	CFO & COO Diversey	Mass General Hospital	VP R&D Teva	CincyTech Ventures
		Pharmaceuticals
cap to $10B as Chairman	Global Head of Oncology	VP Translational Medicine
and CEO	Development Finance,	for CV and Metabolic	VP at Medpace Inc.
	Novartis	Disease, Novartis

4

Baxdrostat(CIN-107) : QD Dosing with Demonstrated Efficacy & Safety

4 Key Drivers of Value and Differentiation

Dosing

Efficacy

Safety

Oral once-daily highly potent treatment with favorable PK/PD profile (>25-hour half life)

SBP reduction seen in blinded, preliminary safety data from ongoing Phase 2 clinical trial (including active doses and placebo) 1

Highly selective inhibition of aldosterone with no observed clinical impact on cortisol

Favorable safety profile in Phase 1 & Phase 2 with no significant electrolyte-related AE's 2

1. Following 12 weeks, systolic blood pressure levels declined for the 124 patients included in the review, including patients in the placebo cohort. The purpose of this blinded data review was to enable an assessment of the overall management and conduct of the trial, without unblinding any individual patient data. Due to the preliminary and blinded nature of the data, this interim data set was not subject to the standard quality control measures typically associated with final clinical trial results.
2. One patient withdrawal due to a hyperkalemia AR in ongoing Phase 2 BrigHtn Trial

QD = Once a day	SBP = Systolic Blood Pressure	5
PK = Pharmacokinetic	AE: = Adverse Effect
PD = Pharmacodynamics